Multiple cardiac ion channels and beta-adrenergic receptors

Multiple cardiac ion channels and beta-adrenergic receptors refers to a broad pharmacological target profile rather than a single molecular entity. This profile encompasses several critical electrophysiological components of the myocardium, including voltage-gated sodium channels, multiple types of potassium channels (notably the rapid delayed rectifier current, IKr), L-type calcium channels, and beta-1 and beta-2 adrenergic receptors (StatPearls, 2023). These proteins are fundamental to the generation and conduction of the cardiac action potential and the regulation of heart rate and contractility in response to autonomic input. In clinical practice, this broad target profile is most relevant to Class III antiarrhythmic drugs, such as amiodarone and dronedarone, which are used to manage complex arrhythmias like atrial fibrillation and ventricular tachycardia (PubMed, PMC2883916). By simultaneously modulating these various channels and receptors, these agents can effectively suppress ectopic activity and stabilize cardiac rhythms, although the lack of specificity often leads to significant safety concerns, including proarrhythmia and extra-cardiac toxicities (NIH, PubChem CID 2157).

Other names

Vaughan-Williams Class III targetsMulti-channel blockersCardiac ion channels and adrenergic receptorsMixed-class antiarrhythmic targets

The mechanism involves the simultaneous inhibition of multiple ion currents: the inward sodium current (Class I effect), the rapid delayed rectifier potassium current (IKr, Class III effect), and the L-type calcium current (Class IV effect), alongside the non-competitive antagonism of beta-1 and beta-2 adrenergic receptors (Class II effect). This combined action results in the prolongation of the action potential duration and the effective refractory period across cardiac tissues (StatPearls, 2023; PubMed, PMC2883916).